Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01AI155052 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| Beth Israel Deaconess Medical Center | OTHER |
| Harvard School of Public Health (HSPH) | OTHER |
Not provided
Not provided
Not provided
This study evaluates strategies to improve access to HIV prevention through the integration of pre-exposure prophylaxis (PrEP) into existing healthcare settings, rather than limiting delivery to specialty clinics. The study addresses barriers to PrEP uptake, including limited awareness, stigma, and restricted access, and recognizes that availability alone may not ensure initiation or sustained use.
The study includes two components. First, a longitudinal cohort of current PrEP users will be followed to assess changes in access, preferences, and PrEP use over time in real-world settings. Second, a dynamic decision-support toolkit will be developed and evaluated to support patients and providers in PrEP-related decision-making. The toolkit will include patient- and provider-facing components to support clinical decision-making, improve risk understanding, and facilitate integration of PrEP into routine healthcare. The toolkit will be refined and beta-tested in selected healthcare facilities in Botswana and Alabama.
Pre-exposure prophylaxis (PrEP) is an evidence-based and effective approach to HIV prevention, yet it has not reached its full potential due to factors such as limited awareness, constrained service resources, and stigma. Currently, most PrEP prescriptions are issued in specialty care settings, offering limited access. Therefore, achieving global implementation goals will require expanding PrEP delivery within other existing health facilities.
Making PrEP available in existing outpatient or inpatient settings alone does not guarantee its initiation or sustained use, even among individuals at risk for HIV acquisition. Appropriate decision-making regarding PrEP use requires collaboration between patients and providers, supported by an enabling clinic infrastructure. Moreover, the PrEP journey can be dynamic, with more PrEP modalities becoming available in recent years, and choices can change over time, underscoring the need for decision-support toolkits that help patients and providers navigate this evolving decision-making process. A decision support toolkit that has components that are either patient- or provider-facing, or both, could enhance patients' risk perception and increase their knowledge of PrEP, enabling them to make informed decisions about its use, as well as decrease the decision-making burden on the provider side.
As such, the investigators aim to (1) propose an implementation strategy that integrates PrEP into existing health facilities and (2) develop a dynamic choice decision support toolkit that supports PrEP integration into these existing health facilities.
Thus, our specific aims are:
Aim 1: To conduct a prospective cohort study of existing PrEP users to better understand how their PrEP access and choices change over time in real-world settings.
Aim 2: To conduct formative work to better understand the landscape of focal points of integration of PrEP into existing healthcare facilities (Aim 2a) and develop and beta-test a dynamic PrEP toolkit prototype needed to support this integration (Aim 2b), in parallel in Botswana and Alabama.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1: Adults Using or Eligible for PrEP | PrEP users - Individuals aged 18 years or older who are currently using or eligible for PrEP |
| |
| Group 2: PrEP Providers and Clinic Administrators | PrEP providers and clinic administrators - Individuals aged 18 years or older who work as PrEP providers or clinic administrators at outpatient clinics or inpatient settings |
| |
| Group 3: Policy Makers and Program Leaders | Policy makers and program leaders - Individuals aged 18 years or older who work as policy makers or program leaders at outpatient clinics or inpatient settings |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Observational cohort (PrEP use in real-world settings) | Other | No intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| PrEP Continuation (Aim 2) | Among participants who initiate PrEP, to determine the proportion who continue PrEP use over 2 years. | Up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| PrEP Initiation (Aim 1) | To determine the number and proportion of participants in the PrEP clinic who initiate PrEP. | Within 2 years after the initial PrEP clinic visit |
| PrEP Switching (Aim 3) |
Not provided
Group 1
Inclusion for Alabama site:
Inclusion for Botswana site:
Exclusion for both sites:
Group 2
Inclusion for both sites:
Exclusion for both sites:
Group 3
Inclusion for both sites:
Exclusion for both sites:
Not provided
Not provided
Not provided
Current PrEP users, providers or clinic administrators, and policy makers or program leaders related to PrEP usage in AL and Botswana
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rena Patel, MD, MPH | Contact | +12059348145 | renapatel@uabmc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Rena Patel, MD, MPH, MPhil | University of Alabama at Birmingham | Principal Investigator |
| Rebecca Zash | Division of Infectious Disease Beth Israel Deaconess Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Princess Marina Hospital | Bontleng | Gaborone | Botswana |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
Not provided
Not provided
Not provided
Among participants who initiate PrEP, to determine the number and proportion who switch between PrEP modalities.
| Up to 2 years |
| PrEP Discontinuation (Aim 4) | Among participants who initiate PrEP, to determine the number and proportion who discontinue PrEP. | Up to 2 years |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |